CCG
ADCT icon

Cypress Capital Group’s ADC Therapeutics ADCT Stock Holding History

Cypress Capital Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,000
Closed -$21.5K – 295
2023
Q2 		$21.5K Buy
+10,000
New +$22.5K ﹤0.01% 298
2022
Q4 		– Sell
-10,000
Closed -$48K – 292
2022
Q3 		$48K Hold
10,000
– – 0.01% 274
2022
Q2 		$80K Buy
+10,000
New +$94.6K 0.01% 277

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $100M AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cypress Capital Group's ADCT Position: Q3 2023 in Review

Cypress Capital Group sold out of ADC Therapeutics (ADCT) in Q3 2023, closing a stake of 10,000 shares — an estimated $21.5K sold.

Cypress Capital Group first reported a position in ADCT in Q2 2022 and held it in 3 quarters. The position peaked at $80K in Q2 2022. 41 funds tracked by Wall St. Rank hold ADCT as of Q3 2023.

  • Cypress Capital Group reported no remaining ADC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Cypress Capital Group sold 10,000 ADC Therapeutics shares in Q3 2023, an estimated $21.5K.
  • Cypress Capital Group first reported a position in ADC Therapeutics in Q2 2022 and held it in 3 quarters.
  • Cypress Capital Group's ADC Therapeutics position peaked at $80K in Q2 2022.
  • 41 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2023.

Based on Cypress Capital Group's 13F filing for Q3 2023, filed 2 Nov 2023.